

**1.Title:** Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

**2.Authors:** Jian Liu\*<sup>1</sup>, YuYing Jiang\*<sup>2</sup>, ZiYue Diao\*<sup>1</sup>, DanDan Chen<sup>1</sup>, RuiYuan Xia<sup>1</sup>, BingWei Wang<sup>#3</sup>, Shuo Yang<sup>#2</sup>, ZhiQiang Yin<sup>#1</sup>.

\* Jian Liu, YuYing Jiang and ZiYue Diao contributed equally to this work.

<sup>1</sup>Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

<sup>2</sup>Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Nanjing, China.

<sup>3</sup>Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, China.

**3.Corresponding authors:**

*ZhiQiang Yin*, Email: [yinzhiqiang@njmu.edu.cn](mailto:yinzhiqiang@njmu.edu.cn)

Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China

*Shuo Yang*, Email: [shuoyang01@njmu.edu.cn](mailto:shuoyang01@njmu.edu.cn)

Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Nanjing, China, 211166

*BingWei Wang*, Email: [bingweiwang@njucm.edu.cn](mailto:bingweiwang@njucm.edu.cn)

Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, China, 210023

**4.Funding sources:** This work was supported by the National Natural Science Foundation of China (82073439 and 82373475).

**5.Conflicts of Interest:** None declared.

**6.Manuscript word count:** 2466 ; **Abstract word count:** 169 ; **References:** 46 ; **Figures:** 4;

**7.Keywords:** psoriasis; neutrophil; pyroptosis; gasdermin D; treatment

### **Declarations**

Ethics approval and consent to participate:

All mice were kept in a barrier facility, and all animal experiments were conducted in accordance with the procedure approved by the Ethical Review Committee for Laboratory Animal Welfare of the Nanjing Medical University (IACUC-2203023). Human skin tissue samples were obtained from the Department of Dermatology, Jiangsu Provincial People's Hospital, which was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Ethics Number: 2020-SRFA-101, and informed consent was obtained from all study participants.

Consent for publication:

All authors agreed with the submission of this manuscript to *eLife* and consent for publication was obtained.

Availability of data and material:

The data and materials are available from the corresponding authors upon reasonable request.

Competing interests: None declared.

Funding: This work was supported by the National Natural Science Foundation of China (82073439 and 82373475).

Authors' contributions:

Jian Liu: Data curation, Investigation, Methodology and Writing - original draft

YuYing Jiang and ZiYue Diao: Data curation, Investigation and Methodology

DanDan Chen and RuiYuan Xia: Methodology

BingWei Wang, Shuo Yan and ZhiQiang Yin: Conceptualization, Project administration, Supervision and Writing - review & editing

Acknowledgements: None.

## Abstract

Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell related abnormalities. Pyroptosis is a type of regulated cell death associated with innate immunity, but its role in psoriasis is unclear. In this study, we found that *gasdermin D* (*Gsdmd*) is higher in human psoriatic skin than that in normal skin, and in imiquimod-induced psoriasis-like mouse skin, the expression of *Gsdmd* was most significantly altered in neutrophils and *Il1b* was also mainly expressed in neutrophils. Immunohistochemical staining of serial sections of skin lesions from psoriasis patients and healthy control also showed that GSDMD expression is higher in psoriasis lesion, especially in neutrophils. *Gsdmd* deficiency mitigates psoriasis-like inflammation in mice. GSDMD in neutrophils contributes to psoriasis-like inflammation, while *Gsdmd* depletion in neutrophils attenuates the development of skin inflammation in psoriasis and reduces the release of the inflammatory cytokines. We found that neutrophil pyroptosis is involved in and contributes to psoriasis inflammation, which provides new insights into the treatment of psoriasis by targeting neutrophil pyroptosis.

## Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

### 1. Introduction

Psoriasis is an autoimmune disease that involves multiple systems and manifests primarily as plaques and scaling. The incidence of psoriasis displays significant variation across populations, with estimates ranging from 0.47% in China to 8.5% in Norway, and 3.0% among adults in the United States[1-3]. The etiology of psoriasis is multi-factorial and involves a complex interplay of genetic, environmental, infectious and lifestyle factors. Previous studies have suggested that the pathogenesis of psoriasis is related to the involvement of various cells, including immune cells, keratinocytes and stromal cells, and the underlying mechanism is complex[4]. The participation of immune cells remains a research focus. Most biologics utilized to treat psoriasis presently target the immune pathway. Current studies suggest that the interleukin 23 (IL-23)/T-helper 17 (Th17) immune axis is the primary immune pathway involved in psoriasis pathogenesis[5]. Th17 cells play a significant role in the pathogenesis of many autoimmune and inflammatory diseases. Th17-derived proinflammatory cytokines, such as IL-17A, IL-17F, and IL-22 are critical in the development of psoriasis[6]. Studies have shown that IL-17A contributes to both an adaptive immune circuit involving specific T-cell subsets and an innate axis between keratinocytes and neutrophils[7]. Except for Th17 cells, Neutrophils within the skin are a hallmark feature of psoriasis. Neutrophils accumulate in the dermis and epidermis, resulting in the formation of Kogoj pustules and Munro microabscesses [8]. Neutrophils are increased in the skin and blood of patients with psoriasis,[9] and promote psoriasis by secreting proinflammatory mediators and proteases through degranulation or forming neutrophil extracellular traps[10-12]. Nevertheless, the mechanisms by which neutrophils promote and exacerbate inflammation in psoriasis remain under investigation.

Pyroptosis is a type of regulated cell death triggered by the inflammasome and mediated by the gasdermin family[13]. Gasdermin D (GSDMD) is currently the most extensively researched member of the gasdermin family. After perturbations of extracellular or intracellular homeostasis related to innate immunity, the classical and non-classical pathways activate caspase 1 and caspase 4/5/11 (caspase 4/5 in humans and caspase 11 in mice)[14], and the activated caspases cleave GSDMD into its N-terminal and C-terminal fragments[15]. The N-terminus of GSDMD forms a transmembrane pore, which releases inflammatory mediators [16, 17]and results in proinflammatory cell death[18]. In recent years, there has been a focus on the role of pyroptosis in infections, tumors, and autoimmune diseases[19-22] due to its potential to cause inflammatory diseases when occurring excessively.

While previous studies have showed that the expression of GSDMD is increased in lesions of patients with psoriasis[23], and the pyroptosis of keratinocytes plays a role in inflammation seen in psoriasis[24]. However, the exact contribution of immune cell pyroptosis to the development of psoriasis remains unclear. Therefore,

our study aimed to investigate the role of GSDMD-mediated immune cell pyroptosis in psoriasis.

## 2. Methods

### 2.1 Experimental animals

All mice were of the species *Mus musculus* (C57BL/6). All experiments were performed with female mice (6–8 weeks old). The *Gsdmd*<sup>-/-</sup> mice were provided by Dr. Feng Shao (National Institute of Biological Sciences, Beijing, China). The *Gsdmd*<sup>fl/fl</sup> mice were generated using conditional gene targeting methods as described previously[25]. All mice were kept in a barrier facility, and all animal experiments were conducted in accordance with the procedure approved by the Ethical Review Committee for Laboratory Animal Welfare of the Nanjing Medical University (IACUC-2203023).

### 2.2 Psoriasis-like mouse model

Psoriasis-like mice were induced by 5% imiquimod (IMQ) cream as previously described [26]. Mice received topical application of 32.5 mg 5% IMQ to the shaved dorsal skin of a limited area (2\*3 cm<sup>2</sup>) for 4 days, and control mice were given the same dose of Vaseline for 4 days. The skin was examined every day, and the dorsa were photographed. The mice were sacrificed by cervical dislocation on day 5, and their skin and serum were collected for the next experiment.

### 2.3 Western blot

Mice back skin tissues were lysed in lysis buffer solution [150 mM NaCl, 10 mM tris (pH 7.4), 5 mM EDTA, 1 mM EGTA, and 0.1%NP-40] supplemented with 1 mM phenylmethylsulphonyl fluoride, and complete protease inhibitor “cocktail” [Sigma-Aldrich]), followed by tissue homogenization and incubation for 60 min at 4°C. The lysates were centrifuged for 10 min at 14,000 g, and supernatants were denatured with SDS buffer, and boiled for 10 min. Proteins were separated by SDS–polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes were immunoblotted with primary antibodies and proteins detected with appropriate secondary anti-rabbit antibody conjugated to fluorescence. Immunoreactivity was visualized by the Odyssey Imaging System (LI-COR Biosciences).

### 2.4 Enzyme-linked immunosorbent assay

Homogenized the mouse back skin tissues (the method is the same as before), and collected the supernatant. Supernatant were collected and measured for the level of IL-1 $\beta$  (DY401) and IL-6 (DY406) according to manufacturer’s instructions by sandwich enzyme-linked immunosorbent assay (ELISA) (R&D System).

### 2.5 Immunofluorescence and Immunohistochemistry staining

For immunofluorescence, the mice skin tissues were collected, fixed in 4% buffered formaldehyde, and embedded in paraffin. Tissue sections were incubated at 4°C overnight with primary antibody to GSDMD (Abcam, ab219800, 1:300) and Ly6G (BDscience, Cat551459, 1:100). Slides were then incubated with indicated secondary antibodies. TUNEL staining was carried out with staining kit (Servicebio). The nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).

Slides were dried and mounted using ProLong Antifade mounting medium (Beyotime Biotechnology). Slides were visualized using a Nikon 50i fluorescence microscope. For immunohistochemical staining, human skin tissue samples were obtained from the Department of Dermatology, Jiangsu Provincial People's Hospital. Our study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Ethics Number: 2020-SRFA-101, and informed consent was obtained from all study participants. Sections were blocked and incubated with primary antibodies to GSDMD (Abcam, ab215203, 1:1000) and CD66b (Biolegend, Cat305102, 1:80) after heat-induced antigen retrieval. Slides were then incubated with horseradish peroxidase-conjugated secondary antibodies. Diaminobenzidine was used for detection. Images were captured with a Nikon 50i microscope. Images were processed using ImageJ 1.53c and AdobePhotoshopCS6 software.

#### 2.6 Flow cytometry (FCM) and Fluorescence Activated Cell Sorting (FACS)

For FCM, skin tissue was digested into single cell suspensions with collagenase P (ROCHE, 1mg/mL), DNaseI (ROCHE, 100 $\mu$ g/ml), and HAase (ABSIN, 10 $\mu$ g/ mL) at 37°C for 1 hour. Single cell suspensions were stained with anti-CD45-Alexa Flour 700 (eBioscience, 1:400), anti-Ly6G-eFlour 450 (eBioscience, 1:400), and FVD eFlour 506 (eBioscience,1:1000) for Flow cytometry (Thermo). After the mice were euthanized, the long bones were separated and the bone marrow was aspirated with a sterile syringe. Single cell suspension was stained with anti-CD45-Alexa Flour 700 (eBioscience, 1:400), anti-CD11b-Percp-cy5.5 (eBioscience, 1:400) and anti-Ly6G-eFlour 450(eBioscience, 1:400) for FACS analysis (Thermo), CD45<sup>+</sup>FVD<sup>-</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils were obtained by FACS. All flow cytometry analyses were performed on an Attune NxT Flow Cytometer (Thermo Fisher Scientific), and data were analyzed using FlowJo 10 software.

#### 2.7 Neutrophil depletion

An injection of anti-Ly6G antibody (Selleck, 200 $\mu$ g) was given on day-1 and day2 during continuous IMQ application to deplete neutrophil in mice.

#### 2.8 Statistical analysis

Data were analyzed using Prism 8 (GraphPad, San Diego, CA, USA). Comparisons between two groups were analyzed by using unpaired Student's t-test. All data are presented as the mean  $\pm$  SEM and are representative of at least three independent experiments.  $P < 0.05$  was considered indicative of statistical significance. \*  $p \leq 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p \leq 0.0001$ , ns  $p > 0.05$ .

### 3. Results

#### 3.1 The GSDMD-mediated pyroptosis is activated in psoriasis.

By searching the GEO database, we found that *Gsdmd* is higher in human psoriatic skin than that in normal skin, and the similar trend was seen in IMQ-induced psoriasis model mice compared to controls (**Fig.1a**). Immunohistochemical staining of serial sections of skin lesions from psoriasis patients and healthy control also showed that GSDMD expression is higher in psoriasis patients (**Fig.1b**). To further elucidate the presence of pyroptosis in psoriasis, we induced a psoriasis-like mouse

model by applying IMQ (**Fig.1c**). The lesions of the mice were collected for western blotting, our results indicated that the IMQ-treated group not only has elevated expression of caspase 1 and GSDMD relative to controls, but also shows functional cleavage of 30KD GSDMD N fragment (**Fig.1d-e**). Hence, the activation of pyroptosis-associated molecules was found in psoriasis lesions.

### 3.2 GSDMD deficiency mitigates psoriasis-like inflammation in mice.

Given the particular elevation of GSDMD levels in psoriasis, we questioned whether GSDMD contributed to psoriasis pathogenesis. We treated WT and GSDMD deficient mice with IMQ to induce psoriasis (**Fig.1c**). We found that the psoriasis area and severity index (PASI) scores were significantly lower in *Gsdmd*<sup>-/-</sup> mice than WT after 4 days of IMQ application (**Fig.2a-b**). Moreover, indicators to assess the severity of psoriasis, including acanthosis, parakeratosis, and microabscess formation as well as infiltration of leukocytes, were less pronounced in *Gsdmd*<sup>-/-</sup> mice compared with WT (**Fig.2c**). We verified the absence of GSDMD in the skin of *Gsdmd*<sup>-/-</sup> mice by western blotting and found that after induction of psoriasis in *Gsdmd*<sup>-/-</sup> mice, the expression and activation of caspase 1, an upstream molecule of pyroptosis, were decreased (**Fig.2d**). Levels of the pro-inflammatory cytokines in protein and mRNA were also examined in the skin using ELISA and quantitative PCR, respectively. Our results showed that the levels of inflammatory cytokines in psoriasis such as IL17a, TNF- $\alpha$ , IL6, IL-1 $\beta$  and IL18 were substantially higher in the WT mice than in the *Gsdmd*<sup>-/-</sup> mice (**Fig.2e-f**). These results demonstrated that the absence of GSDMD ameliorated IMQ-induced psoriasiform dermatitis in mice.

### 3.3 Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.

Previous studies have shown that pyroptosis occurs in psoriasis[24, 27]. Moreover, neutrophils are critical to the pathogenesis of psoriasis, which is usually characterized by a high accumulation of neutrophils both in lesions as well as in blood[28]. Therefore, we wanted to clarify whether neutrophils undergo pyroptosis in psoriasis. Firstly, we searched the GEO database and found that psoriasis patients' neutrophils showed higher expression of GSDMD (**Fig.3a**). Serial sections of skin lesions from psoriasis patients were immunohistochemically stained with CD66b and GSDMD antibodies. We further found that GSDMD was prominently expressed in neutrophils, especially in Munro's microabscesses, which were indicated by CD66b in the patients' skin of both psoriasis vulgaris and pustular psoriasis (**Fig.3b**). Through database search and analysis, we found that in psoriasis-like mouse skin, the expression of *Gsdmd* was most significantly altered in neutrophils (**Fig.3c**). Then, we carried out immunofluorescent analysis of GSDMD in the psoriatic skin tissues of WT mice and GSDMD-deficient mice used as a negative control. Lymphocyte antigen 6 (Ly6G), a classical neutrophil marker[29, 30], was found to be mainly expressed in neutrophils in the skin of IMQ-induced psoriasis-like mice (**S1a**). Therefore, we chose Ly6G as a marker for mouse neutrophils in our experiments. In line with GEO data, immunofluorescence staining showed that GSDMD was more strongly expressed in the mice skin of IMQ applied group than control, including the significant localization

of GSDMD in neutrophils (**Fig.3d**). GSDMD is an effector molecule that mediates pyroptosis. We then found that, compared to the control group, neutrophils infiltrating in IMQ-induced psoriasis-like tissue display a higher expression of pyroptosis-related genes through analyzing the publicly available single-cell transcriptomic data (GSE165021) (**Fig.3e**). These results highlight the role of neutrophil pyroptosis in the progression of psoriasis. To further confirm that these neutrophils underwent pyroptosis, we used flow cytometry to stain PI to confirm neutrophil pyroptosis and performed TUNEL staining on mouse skin after IMQ application to exclude other cell deaths such as apoptosis (**Fig.3f, S1b**), these data suggest that GSDMD-mediated pyroptosis exists in neutrophils infiltrating into psoriatic lesions as shown more PI staining but not change in TUNEL staining in neutrophils.

#### 3.4 GSDMD depletion in neutrophils attenuates the development of skin inflammation in psoriasis.

To investigate the specific effect of neutrophils in psoriasis, we bred *Gsdmd*<sup>fl/fl</sup>; *S100a8*<sup>cre/+</sup> (cKO) mice to make conditionally knockout GSDMD in neutrophils. There are many previous studies using *S100a8*-Cre mice to knockout neutrophil-specific genes[31, 32]. And we found that *S100a8* is mainly expressed in neutrophils and slightly in macrophages in psoriasis-like mouse skin (**S1c**). Therefore, we believe that the knockout effect of GSDMD in cKO mice on other cells is quite small. We isolated bone marrow-derived neutrophils and demonstrated by immunoblotting that GSDMD expression was reduced in cKO neutrophil (**Fig.4a**). Then we applied IMQ to the cKO and control mice (*Gsdmd*<sup>fl/fl</sup>; *S100a8*<sup>+/+</sup>) mice on a continuous basis for 4 days to induce psoriasis. Our results showed that after induction of psoriasis, cKO mice had milder disease than controls, as evidenced by reduced PASI scores and the apparent remission of skin changes shown by HE staining, including acanthosis, parakeratosis, and infiltration of leukocytes (**Fig.4b-d**). And the lower levels of inflammatory cytokines, including IL-17a, TNF- $\alpha$ , IL-6, IL-1 $\beta$  and IL-18, were also showed in cKO mice (**Fig.4e-f**). Notably, although neutrophil-specific deletion of GSDMD mice showed a reduction in psoriasis-like symptoms after induction, the reduction was not as pronounced as in GSDMD full knockout mice, suggesting that additional cellular pyroptosis may also be involved in psoriasis pathogenesis. To further investigate neutrophilic pyroptosis in psoriasis, we detected the expression of GSDMD and its N-terminal fragments by WB in the psoriatic skin of WT mice, *Gsdmd*<sup>-/-</sup> mice and cKO mice. We found that after psoriasis induction, the GSDMD N-terminus was only weakly expressed in the skin of cKO mice, whereas it was strongly expressed in WT mice (**Fig4g**), suggesting that GSDMD-mediated neutrophil pyroptosis is one of the important components of cell pyroptosis in psoriasis. In addition, we used Ly6G antibody to eliminate neutrophils in cKO mice and control mice. It was found that the difference in lesions between the two groups was abolished after neutrophil depletion (**Fig4i, S2a**), indicating that GSDMD in neutrophil plays an important role in the pathogenesis of imiquimod-induced psoriasis-like lesions in mice.

Considering that pyroptosis is a form of regulated cell death that results in inflammation, its effects can be linked to the release of inflammatory cytokines



through membrane pores formed by GSDMD. While neutrophils do undergo pyroptosis, they may exhibit resistance to this cytolytic effect, leading to sustained cytokine release. IL-1 $\beta$ , a significant inflammatory cytokine of pyroptosis, has a crucial function in the pathogenesis of psoriasis. The IL-1 $\beta$ -IL-1R pathway promotes the ailment by regulating IL-17-producing cells in the dermis and stimulating keratinocytes to magnify inflammatory cascades. Therefore, it is hypothesized that the occurrence of neutrophil pyroptosis in psoriasis may activate inflammatory pathways downstream by releasing cytokine IL-1 $\beta$ . In order to further verify our hypothesis, we analyzed publicly available single cell sequencing data. We found that in the skin of psoriasis-like mice, *Il1b* and *Il6* were mainly expressed in neutrophils, while *Il17a* was mainly expressed in T cells, *Il18* was mainly expressed in macrophages and fibroblasts, and *Tnfa* was mainly expressed in macrophages and T cells (**S2b**). This suggests that neutrophil pyroptosis may affect the secretion of cytokines such as IL-1 $\beta$  and IL-6 by neutrophils, thereby affecting the functions of other immune cells such as T cells and macrophages, forming a complex inflammatory network in psoriasis and participating in the pathogenesis of psoriasis.

#### 4 Discussion

In this study, we dissected the role of GSDMD protein, a key pyroptosis executioner, in the context of psoriasis. We found that GSDMD protein was activated in the skin of psoriasis, and that GSDMD in neutrophils promotes psoriasis inflammation through pyroptosis and the release of cytokines. Research on pyroptosis has tended to focus on infections, tumors, and other acute inflammations. Pyroptosis is not only involved in the regulation of sepsis, but also mediates sepsis-related organ damage[33]. This means that while moderate pyroptosis promotes clearance of pathogens, excessive pyroptosis can lead to uncontrolled inflammatory responses and promote the onset and development of sepsis[33-35]. Moreover, pyroptosis promotes severe pancreatitis and associated lung injury through the release of cytokines IL-1 $\beta$  and IL-18[36], and is implicated in acute myocardial injury and spinal cord injury[37, 38]. In addition, GSDMD induced pyroptosis of antigen presenting cells in tumor microenvironments impairs antigen presentation in response to anti-PD-L1 treatment[22]. Only in recent years, studies have explored the function of pyroptosis in psoriasis. Iwona Flisiak et al. found that GSDMD expression was significantly increased in the skin of psoriasis patients, suggesting that it may be involved in the pathogenesis of psoriasis[23]. Xu Chen et al. reported that GSDMD-mediated keratinocyte pyroptosis promotes excessive proliferation and abnormal differentiation induced by the immune microenvironment in psoriatic skin inflammation, thus contributing to the pathogenesis of psoriasis[24]. In addition, there are some studies on pyroptosis-related proteins upstream of GSDMD, such as NLPR3 inflammasome and AIM2 inflammasome, which are involved in and promote psoriasis through downstream inflammatory cytokines[27, 39, 40].

Consistent with earlier research, our study found that the expression of GSDMD and its upstream molecule caspase 1 was upregulated in the skin of psoriasis patients and psoriasis-like mice, indicating that the pyroptosis pathway is activated in psoriasis

skin lesions. Knockout of GSDMD in vivo is effective in significantly ameliorating IMQ-induced psoriasis-like lesions and reducing the level of skin inflammation, which also notably reduces the expression of the pyroptosis-inducing inflammatory cytokine IL-1 $\beta$ . In our study, we found that the upregulated GSDMD signal was more significant in neutrophils in both human and animal tissues. In addition, specific knockout of GSDMD in neutrophils in vivo can also yield results consistent with GSDMD KO mice, although not as obvious as in KO mice. Our study is for the first time demonstrating that GSDMD-mediated neutrophil pyroptosis in psoriasis is involved in psoriatic inflammation and may affect the inflammatory network in psoriasis. Considering the role and early recruitment of neutrophils in psoriasis[28, 41], it is readily accepted that neutrophils act as innate immune cells in response to changes in the microenvironment to initiate pyroptosis signaling and release cytokines to engage and maintain psoriasis inflammation. IL-1 $\beta$  released by pyroptosis may amplify the inflammatory cascade through the IL-1 $\beta$ -IL-1R pathway via direct regulation of dermal IL-17-producing cells and stimulation of keratinocytes[42], thereby contributing to skin inflammation and psoriasis. In addition, the unique resistance of neutrophils to pyroptosis[43] makes it reasonable for them to continuously release cytokines after activation of the pyroptosis pathway and further stimulate skin inflammation.

Our research primarily focuses on the role of neutrophil pyroptosis in psoriasis, this does not conflict with existing reports indicating that KC cell pyroptosis also contributes to disease progression[24]. Both studies underscore the significant role of GSDMD-mediated pyroptotic signaling in psoriasis, and the consistent involvement of KC cells and neutrophils further emphasizes the potential therapeutic value of targeting GSDMD signaling in psoriasis treatment. Nevertheless, combining previous studies and our findings, we can believe that GSDMD-mediated pyroptosis, which is a dynamic biological process, particularly neutrophil pyroptosis, is involved in the inflammation of psoriasis, especially in the early stage. This provides a potential basis for the possible use of drugs targeting pyroptosis, especially drugs targeting neutrophil pyroptosis, in the treatment of psoriasis. Dimethyl fumarate is a type of medicine widely used to treat psoriasis in Europe[44, 45]. The latest research proves that dimethyl fumarate can inhibit the function of GSDMD and thereby inhibit pyroptosis-related inflammation[46].

There is some limitation in our study such as the lack of exploration of upstream signaling involved in neutrophil pyroptosis along with its specific molecular mechanisms. Although we observed significantly increased GSDMD in neutrophils in pustular psoriasis, we were constrained to studying the established PV animal model due to the current absence of a mature GPP animal model. This represents a limitation of our study. Nevertheless, our study showed that neutrophil pyroptosis is involved in and contributes to psoriasis inflammation, indicating potential avenues and foundations for novel psoriasis treatment strategies.

## References:

1. Pezzolo, E. and L. Naldi, *Epidemiology of major chronic inflammatory immune-related*

- skin diseases in 2019*. Expert review of clinical immunology, 2020. **16**(2): p. 155-166.
2. Armstrong, A.W., et al., *Psoriasis prevalence in adults in the United States*. JAMA dermatology, 2021. **157**(8): p. 940-946.
  3. Ding, X., et al., *Prevalence of psoriasis in China: a population-based study in six cities*. European Journal of Dermatology, 2012. **22**(5): p. 663-667.
  4. Guo, J., et al., *Signaling pathways and targeted therapies for psoriasis*. Signal Transduction and Targeted Therapy, 2023. **8**(1): p. 437.
  5. Girolomoni, G., et al., *The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis*. Journal of the European Academy of Dermatology and Venereology, 2017. **31**(10): p. 1616-1626.
  6. Li, B., et al., *The role of Th17 cells in psoriasis*. Immunologic research, 2020. **68**: p. 296-309.
  7. Reich, K., et al., *Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis*. Experimental dermatology, 2015. **24**(7): p. 529-535.
  8. Schön, M.P., S.M. Broekaert, and L. Erpenbeck, *Sexy again: the renaissance of neutrophils in psoriasis*. Experimental dermatology, 2017. **26**(4): p. 305-311.
  9. Rodriguez-Rosales, Y.A., et al., *Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients*. Journal of Allergy and Clinical Immunology, 2021. **148**(4): p. 1030-1040.
  10. Wang, Z. and D. Shi, *Research progress on the neutrophil components and their interactions with immune cells in the development of psoriasis*. Skin Research and Technology, 2023. **29**(7): p. e13404.

11. Chen, J., et al., *Neutrophils enhance cutaneous vascular dilation and permeability to aggravate psoriasis by releasing matrix metalloproteinase 9*. *Journal of Investigative Dermatology*, 2021. **141**(4): p. 787-799.
12. Shao, S., et al., *Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk*. *Frontiers in immunology*, 2019. **10**: p. 746.
13. Galluzzi, L., et al., *Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018*. *Cell Death & Differentiation*, 2018. **25**(3): p. 486-541.
14. Kesavardhana, S., R.S. Malireddi, and T.-D. Kanneganti, *Caspases in cell death, inflammation, and pyroptosis*. *Annual review of immunology*, 2020. **38**: p. 567-595.
15. Kovacs, S.B. and E.A. Miao, *Gasdermins: effectors of pyroptosis*. *Trends in cell biology*, 2017. **27**(9): p. 673-684.
16. Evavold, C.L., et al., *The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages*. *Immunity*, 2018. **48**(1): p. 35-44. e6.
17. Heilig, R., et al., *The Gasdermin-D pore acts as a conduit for IL-1 $\beta$  secretion in mice*. *European journal of immunology*, 2018. **48**(4): p. 584-592.
18. Banerjee, I., et al., *Gasdermin D restrains type I interferon response to cytosolic DNA by disrupting ionic homeostasis*. *Immunity*, 2018. **49**(3): p. 413-426. e5.
19. You, R., et al., *Pyroptosis and its role in autoimmune disease: a potential therapeutic target*. *Frontiers in immunology*, 2022. **13**: p. 841732.
20. Fang, Y., et al., *Pyroptosis: a new frontier in cancer*. *Biomedicine & Pharmacotherapy*,

2020. **121**: p. 109595.
21. Yu, P., et al., *Pyroptosis: mechanisms and diseases*. Signal transduction and targeted therapy, 2021. **6**(1): p. 128.
  22. Jiang, Y., et al., *Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade*. Cell Reports, 2022. **41**(4).
  23. Nowowiejska, J., et al., *Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin—A New Potential Link in the Pathogenesis of Psoriasis*. International Journal of Molecular Sciences, 2023. **24**(17): p. 13047.
  24. Lian, N., et al., *Gasdermin D-mediated keratinocyte pyroptosis as a key step in psoriasis pathogenesis*. Cell Death & Disease, 2023. **14**(9): p. 595.
  25. Li, S., et al., *Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis*. Journal of Experimental Medicine, 2019. **216**(11): p. 2562-2581.
  26. Kim, S.H., et al., *Pellino-1 promotes intrinsic activation of skin-resident IL-17A-producing T cells in psoriasis*. Journal of Allergy and Clinical Immunology, 2023. **151**(5): p. 1317-1328.
  27. Deng, G., et al., *Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice*. International Immunopharmacology, 2019. **74**: p. 105682.
  28. Chiang, C.-C., et al., *Neutrophils in psoriasis*. Frontiers in immunology, 2019. **10**: p. 2376.

29. Ding, Y., et al., *Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis*. *Cell Death & Disease*, 2022. **13**(11): p. 996.
30. Xie, X., et al., *Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection*. *Nature immunology*, 2020. **21**(9): p. 1119-1133.
31. Stackowicz, J., et al., *Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome*. *Journal of Experimental Medicine*, 2021. **218**(10): p. e20201466.
32. Abram, C.L., et al., *Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice*. *Immunity*, 2013. **38**(3): p. 489-501.
33. Zheng, X., et al., *The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review*. *Frontiers in immunology*, 2021. **12**: p. 711939.
34. Aglietti, R.A. and E.C. Dueber, *Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions*. *Trends in immunology*, 2017. **38**(4): p. 261-271.
35. Shi, J., et al., *Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death*. *Nature*, 2015. **526**(7575): p. 660-665.
36. Wu, J., et al., *Treatment of severe acute pancreatitis and related lung injury by targeting gasdermin D-mediated pyroptosis*. *Frontiers in cell and developmental biology*, 2021. **9**: p. 780142.
37. Shi, H., et al., *GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury*. *Circulation research*, 2021. **129**(3): p. 383-396.

38. Al Mamun, A., et al., *Role of pyroptosis in spinal cord injury and its therapeutic implications*. Journal of Advanced Research, 2021. **28**: p. 97-109.
39. Verma, D., et al., *Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation*. Journal of Investigative Dermatology, 2021. **141**(3): p. 586-595.  
e5.
40. Zhang, C., et al., *Analysis of the potential pyroptosis mechanism in psoriasis and experimental validation of NLRP3 in vitro and in vivo*. International Immunopharmacology, 2023. **124**: p. 110811.
41. Wang, W.-M. and H.-Z. Jin, *Role of neutrophils in psoriasis*. Journal of Immunology Research, 2020. **2020**.
42. Cai, Y., et al., *A critical role of the IL-1 $\beta$ -IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis*. Journal of investigative Dermatology, 2019. **139**(1): p. 146-156.
43. Dąbrowska, D., et al., *Many ways—one destination: different types of neutrophils death*. International Reviews of Immunology, 2019. **38**(1): p. 18-32.
44. Mrowietz, U., et al., *Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus*. Journal of the European Academy of Dermatology and Venereology, 2018. **32**: p. 3-14.
45. Mrowietz, U. and K. Asadullah, *Dimethylfumarate for psoriasis: more than a dietary curiosity*. Trends in molecular medicine, 2005. **11**(1): p. 43-48.
46. Humphries, F., et al., *Succination inactivates gasdermin D and blocks pyroptosis*. Science, 2020. **369**(6511): p. 1633-1637.





### Figure legends:

Figure1. The GSDMD-mediated pyroptosis is activated in psoriasis.

a) Expression of GSDMD in patients with psoriasis patients and healthy people from GSE178197, GSE161683 and GSE153007.

b) Representative immunohistochemical staining of GSDMD in sections of skin tissue from healthy individuals and patients with psoriasis (n=3-5, each group). Scale bar =100µm.

c) Schematic representation of the IMQ-induced psoriasis mouse model.

d) Representative images and statistical analysis of western blot analysis showing the expression of GSDMD and its N-terminal fragments in dorsal skin of WT mice treated with vehicle or IMQ at day 4 (n=4).

e) Representative images and statistical analysis of western blot analysis showing the expression level of pro-caspase1 and caspase1 in dorsal skin of WT mice treated with vehicle or IMQ at day 4.

psn, psoriasis non-lesional skin; ps, psoriasis skin; con, control; HD, healthy donor; GPP, generalized pustular psoriasis; IMQ, imiquimod; WT, wild-type. Error bars show mean ± SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P ≤ 0.0001. Data are representative of three independent experiments for (b, d, e).

Figure2. GSDMD deficiency mitigates psoriasis-like inflammation in mice.

a) Macroscopic phenotypic representation of the dorsal skin in WT and GSDMD-KO mice treated with IMQ at day 4.

b) Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=10-12).

c) Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal skin in WT and GSDMD-KO mice treated with IMQ at day 4 (n=5). Scale bar =100µm.

d) Representative images and statistical analysis of western blot analysis showing the expression level of GSDMD and caspase1 in dorsal skin of WT and GSDMD-KO mice treated with IMQ at day 4 (n=4).

e) Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in the dorsal skin of WT and GSDMD-KO mice treated with IMQ at day 4 (n = 4). Data were normalized to a reference gene, Gapdh.

f) ELISA analysis of IL-6 and IL-1β per 1 mg of the dorsal skin from WT and GSDMD-KO mice treated with IMQ at day 4 (n=5).

IMQ, imiquimod; WT, wild-type; KO, knockout; PASI, psoriasis Area and Severity Index. Error bars show mean ± SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. Data are representative of three independent experiments for (a, c, d).

Figure3. Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.

a) Expression of GSDMD in neutrophils in psoriasis patients and healthy people from GSE123785.

b) Representative immunohistochemical staining of CD66b and GSDMD in two consecutive sections of skin tissue from patients with psoriasis vulgaris or generalized pustular psoriasis (left); representative immunohistochemical staining of CD66b (brown) and GSDMD (red) in sections of skin tissue from patients with psoriasis vulgaris (n=3-5, each group). Scale bar =100µm.

- e) Dot plot of *Gsdmd* expression in each cell type in the skin of IMQ-induced psoriasis-like mice (GSE165021).
  - d) Representative immunofluorescence of GSDMD (red), Ly6G (green) and nuclear (blue) in dorsal skin of WT mice treated with vehicle, WT mice treated with IMQ and GSDMD-KO mice treated with IMQ at day 5. Scale bar =50 $\mu$ m.
  - e) ssGSEA analysis showed the expression of pyroptosis-related genes in neutrophils infiltrating in control and IMQ-induced psoriasis-like tissue (GSE165021).
  - f) Representative and statistical graphs of the mean fluorescence intensity of propidium iodide in neutrophils from skin of WT mice as detected by flow cytometry(n=3).
- ps, psoriasis skin; con, control; PV, psoriasis vulgaris; GPP, generalized pustular psoriasis; IMQ, imiquimod; WT, wild-type; MFI, mean fluorescence intensity; PI, propidium iodide; MFO, Fluorescence Minus One. Error bars show mean  $\pm$  SEM. \*P < 0.05, \*\*\*\*P < 0.0001. Data are representative of three independent experiments for (b, d-e).

Figure4. GSDMD depletion in neutrophils attenuates the development of skin inflammation in psoriasis.

- a) Representative images of western blot showing the expression of GSDMD in bone marrow-derived neutrophils of cKO and isotype control mice.
- b) Macroscopic phenotypic representation of the dorsal skin in control and GSDMD-cKO mice treated with IMQ at day 4.
- c) Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=7).
- d) Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal skin in control and GSDMD-cKO mice treated with IMQ at day 4 (n=5). Scale bar =100 $\mu$ m.
- e) Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in the dorsal skin of control and GSDMD-cKO mice treated with IMQ at day 4 (n = 4). Data were normalized to a reference gene, Gapdh.
- f) ELISA analysis of IL-6 and IL-1 $\beta$  per 1 mg of the dorsal skin from control and GSDMD-cKO mice treated with IMQ at day 4(n=5).
- g) Representative images and statistical analysis of western blot analysis showing the expression level of GSDMD and its N-terminal fragments in dorsal skin of WT, cKO and *Gsdmd*<sup>-/-</sup> mice treated with IMQ at day 4 (n=4).
- h) Schematic representation of the use of anti-Ly6G antibody in the IMQ-induced psoriasis mouse model.
- i) Macroscopic phenotypic representation and PASI score of cKO mice and control mice treated with IMQ and Ly6G antibody.

cKO, conditional knockout. Error bars show mean  $\pm$  SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. Data are representative of three independent experiments for (a, b, d, g, i).

Figure S1

- a) Expression level of *Ly6g* in each cell type in the skin of IMQ-induced psoriasis-like mice (GSE165021).

- b)** Representative immunofluorescence of TUNEL (red), Ly6G (green) and nuclear (blue) in dorsal skin of WT mice treated with IMQ and GSDMD-KO mice treated with IMQ at day 4. Scale bar =50 $\mu$ m. Statistical analysis of ratio of TUNEL positive cells in neutrophils. (n=7)
- c)** Expression level of *S100a8* in each cell type in the skin of IMQ-induced psoriasis-like mice (GSE165021).

Error bars show mean  $\pm$  SEM. ns,  $P \geq 0.05$ . Data are representative of three independent experiments for (b).





#### Figure S2

- a)** Flow cytometry plots of neutrophil, isolated from dorsal skin of WT mice treated with IMQ.
- b)** Uniform Manifold Approximation and Projection (UMAP) of single cells isolated from the skin of IMQ-induced psoriasis-like mice (GSE165021), and feature plots showing expression of *Il17a*, *Il6*, *Tnfa*, *Il1b* and *Il18* (n=2).

Data are representative of three independent experiments for (a).


# Figure.1

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.10.24310231>; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.




# Figure.2

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.10.24310231>; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



# Figure.3



# Figure.4

